Neoadjuvant or Adjuvant Therapy for Resectable or Borderline Resectable Pancreatic Cancer: Which Is Preferred?

ABSTRACT:

SUBMITTER: O'Reilly EM 

PROVIDER: S-EPMC7255981 | biostudies-literature | 2020 Jun

REPOSITORIES: biostudies-literature